CMAB Biopharma (Suzhou) Inc, a dedicated biologics contract manufacturing and development organisation, has named Ye Shi as head of quality, it was reported on Thursday.

In the new role, Ye Shi will be responsible for the overall management of the quality system within the company.

Over the last 30 years, Ye Shi has worked in biopharmaceutical companies in both China and the United States. Before joining CMAB, he served as the deputy general manager and quality assurance director at QILU Pharmaceutical Co Ltd.

Additionally, he led the quality team to successfully pass the European QP audit, laying the foundation for clinical trials in the EU and internationally. Furthermore, he has served as the corporate QA and compliance director of the PDI Company in the United States, guiding the quality team of a Chinese CMO quality unit through site inspections by FDA and Health Canada. He previously served as site quality head and quality assurance director at Immunomedics in the United States. Earlier, he worked at Wyeth Lederle, The Validation Group, and Sino-American Shanghai Squibb Pharmaceuticals.